Helle Al-Hakem1, Søren H Sindrup2, Henning Andersen3, Charlotte Dornonville de la Cour4, Lisbeth L Lassen5, Bianca van den Berg6, Bart C Jacobs7, Thomas Harbo3. 1. Department of Neurology, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, Denmark. helsma@rm.dk. 2. Department of Neurology, Odense University Hospital, Odense, Denmark. 3. Department of Neurology, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, Denmark. 4. Department of Clinical Neurophysiology, Rigshospitalet, Copenhagen, Denmark. 5. Department of Neurology, Rigshospitalet Glostrup, Copenhagen, Denmark. 6. Department of Neurology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands. 7. Department of Neurology and Immunology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.
Abstract
OBJECTIVES: To describe the epidemiology and clinical heterogeneity of Guillain-Barré syndrome (GBS) in Denmark and to compare a population-based cohort to prospectively included patients in the International GBS Outcome Study (IGOS). METHODS: The incidence rate (IR) of GBS in Denmark from September 2012 to December 2015, applying the National Institute of Neurological Disorders and Stroke (NINDS) diagnostic criteria, was estimated and the level of diagnostic certainty was described with the Brighton criteria. All cases registered with a diagnosis of GBS or other inflammatory neuropathies in the Danish National Hospital Registry were reviewed for diagnostic criteria and for information on treatment and clinical course. RESULTS: A total of 299 GBS cases were confirmed, corresponding to a crude IR of 1.59 (95% CI 1.42-1.78) per 100,000 per year. The Brighton criteria level 1-3 of diagnostic certainty was met in 279 (93%) of the patients. Thirty-five percent of the patients were mildly affected (GBS disability score < 3) and a correlation between high age and high disability score at nadir was found (Spearman's rank correlation coefficient 0.42, p < 0.0001). The group of 89 (30%) patients who were enrolled in IGOS had higher GBS disability score at nadir, were admitted 5 days earlier, reached nadir 4 days faster, and a larger proportion received treatment with IVIg (all p < 0.05). CONCLUSION: The epidemiology and full clinical spectrum of GBS are described in a population-based study. This includes a larger proportion of milder cases that are underrepresented in prospective cohorts such as IGOS.
OBJECTIVES: To describe the epidemiology and clinical heterogeneity of Guillain-Barré syndrome (GBS) in Denmark and to compare a population-based cohort to prospectively included patients in the International GBS Outcome Study (IGOS). METHODS: The incidence rate (IR) of GBS in Denmark from September 2012 to December 2015, applying the National Institute of Neurological Disorders and Stroke (NINDS) diagnostic criteria, was estimated and the level of diagnostic certainty was described with the Brighton criteria. All cases registered with a diagnosis of GBS or other inflammatory neuropathies in the Danish National Hospital Registry were reviewed for diagnostic criteria and for information on treatment and clinical course. RESULTS: A total of 299 GBS cases were confirmed, corresponding to a crude IR of 1.59 (95% CI 1.42-1.78) per 100,000 per year. The Brighton criteria level 1-3 of diagnostic certainty was met in 279 (93%) of the patients. Thirty-five percent of the patients were mildly affected (GBS disability score < 3) and a correlation between high age and high disability score at nadir was found (Spearman's rank correlation coefficient 0.42, p < 0.0001). The group of 89 (30%) patients who were enrolled in IGOS had higher GBS disability score at nadir, were admitted 5 days earlier, reached nadir 4 days faster, and a larger proportion received treatment with IVIg (all p < 0.05). CONCLUSION: The epidemiology and full clinical spectrum of GBS are described in a population-based study. This includes a larger proportion of milder cases that are underrepresented in prospective cohorts such as IGOS.
Entities:
Keywords:
Brighton criteria; Epidemiology; Guillain–Barré syndrome; IGOS; International GBS outcome study
Authors: Iain M Carey; Emma Banchoff; Niranjanan Nirmalananthan; Tess Harris; Stephen DeWilde; Umar A R Chaudhry; Derek G Cook Journal: PLoS One Date: 2021-12-31 Impact factor: 3.240
Authors: Luíza Morais de Matos; Ariely Teotonio Borges; Aline Barbosa Palmeira; Vinicius Moreira Lima; Ernane Pires Maciel; Rubens Nelson Morato Fernandez; João Pedro Lima Mendes; Gustavo Adolfo Sierra Romero Journal: Rev Soc Bras Med Trop Date: 2022-04-08 Impact factor: 2.141
Authors: Christine Verboon; Thomas Harbo; David R Cornblath; Richard A C Hughes; Pieter A van Doorn; Michael P Lunn; Kenneth C Gorson; Fabio Barroso; Satoshi Kuwabara; Giuliana Galassi; Helmar C Lehmann; Susumu Kusunoki; Ricardo C Reisin; Davide Binda; Guido Cavaletti; Bart C Jacobs Journal: J Neurol Neurosurg Psychiatry Date: 2021-06-08 Impact factor: 10.154